Total Payments
$7,726
2024 Payments
$776.66
Companies
36
Transactions
529
Medicare Patients
10,507
Medicare Billing
$1.1M
Payment Breakdown by Category
Food & Beverage$7,670 (99.3%)
Education$55.62 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $7,670 | 522 | 99.3% |
| Education | $55.62 | 7 | 0.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $894.43 | 74 | $0 (2024) |
| Amgen Inc. | $865.26 | 67 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $860.96 | 67 | $0 (2024) |
| Esperion Therapeutics, Inc. | $839.09 | 38 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $697.59 | 54 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $533.73 | 54 | $0 (2024) |
| Impulse Dynamics (USA) Inc. | $372.98 | 10 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $353.65 | 24 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $324.26 | 19 | $0 (2024) |
| Boston Scientific Corporation | $227.38 | 12 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $776.66 | 45 | E.R. Squibb & Sons, L.L.C. ($165.24) |
| 2023 | $705.57 | 36 | Impulse Dynamics (USA) Inc. ($159.18) |
| 2022 | $586.66 | 42 | Impulse Dynamics (USA) Inc. ($145.91) |
| 2021 | $1,673 | 91 | Esperion Therapeutics, Inc. ($714.50) |
| 2020 | $599.17 | 49 | Janssen Pharmaceuticals, Inc ($172.23) |
| 2019 | $1,009 | 83 | SANOFI-AVENTIS U.S. LLC ($257.36) |
| 2018 | $1,186 | 107 | Novartis Pharmaceuticals Corporation ($241.69) |
| 2017 | $1,189 | 76 | Janssen Pharmaceuticals, Inc ($229.95) |
All Payment Transactions
529 individual payment records from CMS Open Payments — Page 1 of 22
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $14.98 | General |
| Category: Cardiovascular | ||||||
| 12/10/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $13.64 | General |
| Category: Cardiovascular | ||||||
| 11/26/2024 | Inspire Medical Systems, Inc. | INSPIRE (Device) | Food and Beverage | In-kind items and services | $22.12 | General |
| Category: NEUROLOGY | ||||||
| 11/19/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $17.59 | General |
| Category: DIABETES | ||||||
| 11/14/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $5.42 | General |
| Category: Cardiovascular | ||||||
| 11/04/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $15.92 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/31/2024 | Lexicon Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $13.39 | General |
| 10/28/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $13.91 | General |
| Category: Cardiovascular | ||||||
| 10/25/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $14.52 | General |
| Category: Cardiovascular | ||||||
| 10/25/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $1.32 | General |
| Category: Cardiovascular | ||||||
| 10/15/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $17.59 | General |
| Category: DIABETES | ||||||
| 10/07/2024 | Boston Scientific Corporation | WATCHMAN FLX (Device) | Food and Beverage | In-kind items and services | $25.66 | General |
| Category: WATCHMAN FLX_IC | ||||||
| 09/26/2024 | ABIOMED | Impella (Device) | Food and Beverage | Cash or cash equivalent | $21.32 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/12/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $14.33 | General |
| Category: DIABETES | ||||||
| 09/10/2024 | HEARTFLOW, INC. | FFRct (Device) | Food and Beverage | Cash or cash equivalent | $23.04 | General |
| Category: Coronary | ||||||
| 09/04/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $16.53 | General |
| Category: DIABETES | ||||||
| 09/03/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $15.99 | General |
| Category: Heart Failure and Hypertension | ||||||
| 08/29/2024 | Regeneron Healthcare Solutions, Inc. | EVKEEZA (Biological) | Food and Beverage | In-kind items and services | $17.94 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 08/16/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $4.64 | General |
| Category: Cardiovascular | ||||||
| 08/13/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $8.50 | General |
| Category: Cardiovascular | ||||||
| 08/05/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $19.00 | General |
| Category: DIABETES | ||||||
| 07/30/2024 | HEARTFLOW, INC. | FFRct (Device) | Food and Beverage | Cash or cash equivalent | $27.04 | General |
| Category: Coronary | ||||||
| 07/24/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $15.38 | General |
| Category: CARDIOVASCULAR | ||||||
| 07/23/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $14.18 | General |
| Category: Heart Failure and Hypertension | ||||||
| 06/17/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $14.90 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 2,564 | 3,776 | $1.0M | $273,420 |
| 2022 | 19 | 2,841 | 4,153 | $1.1M | $298,974 |
| 2021 | 19 | 2,649 | 4,018 | $1.1M | $287,089 |
| 2020 | 20 | 2,453 | 3,652 | $839,326 | $229,209 |
Total Patients
10,507
Total Services
15,599
Medicare Billing
$1.1M
Procedure Codes
75
All Medicare Procedures & Services
75 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 667 | 1,326 | $376,584 | $127,177 | 33.8% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 147 | 149 | $182,282 | $43,268 | 23.7% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 323 | 332 | $169,152 | $39,542 | 23.4% |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | Office | 2023 | 102 | 111 | $81,592 | $15,142 | 18.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 78 | 78 | $28,470 | $9,304 | 32.7% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 52 | 208 | $30,784 | $9,228 | 30.0% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 539 | 741 | $40,755 | $7,989 | 19.6% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 112 | 114 | $26,790 | $6,207 | 23.2% |
| G0249 | Provision of test materials and equipment for home inr monitoring of patient with either mechanical heart valve(s), chronic atrial fibrillation, or venous thromboembolism who meets medicare coverage criteria; includes: provision of materials for use in the | Office | 2023 | 11 | 87 | $32,625 | $4,864 | 14.9% |
| 93356 | Heart muscle strain imaging | Office | 2023 | 118 | 121 | $16,335 | $3,980 | 24.4% |
| 93244 | Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 114 | 121 | $9,559 | $2,075 | 21.7% |
| 93242 | Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 113 | 120 | $6,240 | $1,312 | 21.0% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Office | 2023 | 64 | 65 | $4,550 | $1,126 | 24.8% |
| 93248 | Heart rhythm review and interpretation of continous external ekg over 8-15 days | Office | 2023 | 34 | 38 | $3,306 | $721.10 | 21.8% |
| G0250 | Physician review, interpretation, and patient management of home inr testing for patient with either mechanical heart valve(s), chronic atrial fibrillation, or venous thromboembolism who meets medicare coverage criteria; testing not occurring more frequent | Office | 2023 | 11 | 82 | $2,460 | $570.76 | 23.2% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Office | 2023 | 45 | 45 | $2,250 | $508.26 | 22.6% |
| 93246 | Heart rhythm recording of continous external ekg over 8-15 days | Office | 2023 | 34 | 38 | $1,976 | $406.26 | 20.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 639 | 1,337 | $379,708 | $129,513 | 34.1% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2022 | 186 | 186 | $206,790 | $52,833 | 25.5% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2022 | 378 | 387 | $187,126 | $45,180 | 24.1% |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | Office | 2022 | 118 | 127 | $95,914 | $17,161 | 17.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 97 | 97 | $35,075 | $12,174 | 34.7% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 569 | 809 | $44,495 | $8,929 | 20.1% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2022 | 39 | 156 | $23,088 | $7,540 | 32.7% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2022 | 118 | 118 | $27,730 | $6,515 | 23.5% |
About Dr. John Saia, DO
Dr. John Saia, DO is a Cardiovascular Disease healthcare provider based in Hammonton, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1346229911.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Saia, DO has received a total of $7,726 in payments from pharmaceutical and medical device companies, with $776.66 received in 2024. These payments were reported across 529 transactions from 36 companies. The most common payment nature is "Food and Beverage" ($7,670).
As a Medicare-enrolled provider, Saia has provided services to 10,507 Medicare beneficiaries, totaling 15,599 services with total Medicare billing of $1.1M. Data is available for 4 years (2020–2023), covering 75 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Hammonton, NJ
- Active Since 01/12/2006
- Last Updated 10/23/2024
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1346229911
Products in Payments
- XARELTO (Drug) $853.99
- ENTRESTO (Drug) $799.35
- Corlanor (Drug) $527.05
- NEXLIZET (Drug) $500.66
- ELIQUIS (Drug) $447.45
- PRALUENT (Drug) $358.67
- MULTAQ (Drug) $338.92
- NEXLETOL (Drug) $338.43
- Repatha (Biological) $322.87
- JARDIANCE (Drug) $300.78
- VERQUVO (Drug) $206.43
- FARXIGA (Drug) $195.80
- Livalo (Drug) $171.37
- OPTIMIZER (Device) $159.18
- Vascepa (Drug) $153.11
- Optimizer (Device) $145.91
- CAMZYOS (Drug) $126.43
- WATCHMAN (Device) $98.66
- LEQVIO (Drug) $95.08
- BRILINTA (Drug) $92.03
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.